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ABSTRACT 
Background: Preference for and acceptability of a drug are crucial for com- 
pliance and hence optimal treatment of diseases that require long-term manage- 
ment (eg, osteoporosis). The preference for and acceptability of a chewable 
tablet containing calcium and vitamin D 3 and a dose-comparable effervescent 
powder were assessed in a Phase 4, randomized, open-label, crossover trial in 
5 European countries (Sweden, Finland, Belgium, the Netherlands, and Greece). 
Objective: The aim of the present analysis was to compare the preference 
for and acceptability, including tolerability, of these 2 formulations based on the 
Belgian results of the previously mentioned study. 
Methods: Patients were recruited from 3 osteoporosis units and university 
hospitals in Brussels, Liege, and Ghent, Belgium. Adult patients at risk for calci- 
um and vitamin D deficiencies were enrolled. The study drugs included 2 formu- 
lations of a dietary supplement containing a combination of calcium plus vita- 
min D3: chewable tablets (calcium carbonate, 1250 mg; vitamin D 3, 400 IU) (A) 
and effervescent powder (calcium carbonate, 1250 mg; vitamin D 3, 440 IU) (I3). 
Patients were randomly assigned to receive 1 of 2 treatment sequences: AB or 
BA. Both formulations were given PO BID for 14 days, with a switch to the alter- 
nate formulation occurring on day 15 of the study. Preference and acceptability 
were assessed using 2 questionnaires: one assessed 5 variables of acceptability 
using 11-point scales, and the other assessed preference using yes/no questions. 
Compliance and tolerability were recorded throughout the study, with unused 
dose counts and recording of adverse vents (AEs), respectively. 
Results: The study comprised 200 patients, 199 of whom received at least 
1 dose of study medication and were included in the intent-to-treat nalysis 
(174 women, 25 men; mean age, 66 years [range, 30-87 years]). Preference data were 
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available in 178 patients, 129 of whom (72.5%) preferred the chewable tablet 
compared with 34 (19.1%) who preferred the effervescent powder and 15 (8.4%) 
who had no preference (both, P < 0.001 vs tablet). The preference for the tablet 
was based on consistently and significantly higher mean scores on all 5 vari- 
ables of acceptability (all, P< 0.001). The most common AEs were gastrointesti- 
nal (tablet, 27/192 patients [14.1%]; powder, 31/190 patients [16.3%]). Eighteen 
patients (9.0%) discontinued the trial due to >1 AE (12 receiving the tablet and 
6 receiving the powder). 
¢onduslons: In this study of preference for and acceptability of 2 formula- 
tions (chewable tablet and effervescent powder) of a dietary supplement con- 
taining a combination of calcium plus vitamin D 3 in Belgian adults at risk for 
calcium and vitamin D deficiencies, the chewable tablet was preferred by a sig- 
nificant majority. Based on 5 variables, the tablet was found to be significantly 
more acceptable than the powder. Tolerability was similar between the 2 for- 
mulations. (Curr Ther Res Clin Exp. 2005;66:23-34) Copyright © 2005 Excerpta 
Medica, Inc. 
Key words: acceptance, calcium, elderly, formulation, osteoporosis, prefer- 
ence, vitamin D 3. 
INTRODUCTION 
The aim of pharmacotherapy in primary and secondary osteoporosis to pre- 
vent bone fractures. Dietary supplements containing calcium and/or vitamin D3, 
sometimes in combination with bisphosphonates, hormone replacement thera- 
py, or calcitonin, are widely used for the prevention and treatment of calcium 
deficiency, vitamin D 3 deficiency, and/or osteoporosis. A stand-alone regimen of 
a supplement containing calcium plus vitamin D 3 decreases bone mineral den- 
sity (BMD) loss and thus the risk for fractures. This treatment also prevents 
hypocalcemic reactions to inhibitors of bone resorption, which in turn stimu- 
lates parathyroid hormone secretion. 
With the drugs currently available for the treatment of osteoporosis, long- 
term (possibly lifelong) dosing is needed for treatment success. 1-4 However, 
pharmacotherapy may be complicated by adverse events (AEs) or inconven- 
ient dosing, leading to poor treatment compliance. S,6 It has also been suggested 
that compliance with long-term oral therapy is related to the taste, size, and 
formulation of the drug. 7-9 For example, pleasant aste and oral sensation are 
important for compliance with chewable tablets. 7-9 
The preference for and acceptability of a chewable tablet containing calci- 
um and vitamin D 3 and a dose-comparable effervescent powder were assessed 
in a Phase 4, randomized, open-label, crossover trial in 5 European countries 
(Sweden, Finland, Belgium, the Netherlands, and Greece). 1° The aim of the 
present analysis was to compare the preference for and acceptability, includ- 
ing tolerability, of these 2 formulations based on the Belgian results of that 
study. 
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PA11ENTS AND METHODS 
Study Design 
The protocol of the European study complied with the current version of the 
Declaration of Helsinki and its amendments and the good clinical practice 
guidelines. In Belgium, the ethics committees at each of the 3 study sites and 
the Agency of Medicines, Brussels, Belgium, approved the protocol of the trial, 
which was conducted between July 2002 and September 2003. 
Indusion and Exclusion Criteria 
Patients aged >18 years at risk for calcium and vitamin D deficiencies, deter- 
mined using physician assessment and the indications in the package inserts of 
the 2 trial medications, 11,12 were recruited from 3 osteoporosis units and uni- 
versity hospitals in Brussels, Liege, and Ghent, Belgium. 
Patients were excluded if they had received either study medication within 
6 months before the study, had any condition for which the trial drugs were 
contraindicated (eg, hypercalcemia, hypercalciuria, Zollinger-Ellison syndrome, 
nephrolithiasis), or were to undergo surgery during the 28-day study period. 
Pregnant, possibly pregnant, or breastfeeding women were excluded from 
the study. Women of childbearing age were required to use an effective method 
of birth control throughout the study. 
Participation in the study was voluntary and unpaid. However, patients were 
offered compensation for transportation to and from the study sites. 
Study Drug Administration 
The trial drugs included 2 formulations of a dietary supplement containing 
a combination of calcium plus vitamin D3: chewable tablets* (calcium carbon- 
ate, 1250 mg; vitamin D3, 400 IU) (A) and effervescent powdert (calcium car- 
bonate, 1250 mg; vitamin D 3, 440 IL0 to be dissolved in 150 mL of water (B). 
Using a computer-generated list of random numbers, patients were randomly 
assigned to receive 1 of 2 treatment sequences: AB or BA. Both formula- 
tions were given PO BID (morning and evening) for 14 days, which was con- 
sidered an adequate duration for a patient o become sufficiently familiar with 
the formulation to assess preference and acceptability. Both formulations 
were distributed to patients in the original packaging (60 tablets or 30 sachets 
of powder). Patients receiving drugs known to interact with the trial drugs 
(eg, digoxin, tetracycline, fluoroquinolones, bisphosphonates, iron, sodium 
fluoride, diuretics, phenytoin, barbiturates, corticosteroids, ievothyroxine, ion 
exchange resins, laxatives) were instructed not to take the supplement at the 
same time as the medication in question (eg, to take the supplement 3 hours 
before or after bisphosphonate dosing). 
*Trademark: Steovit D3 ® (Nycomed Christiaens SCA, Brussels, Belgium). 
tTrademark: Calcit D~ (Procter & Gamble, Strombeek-Bever, Belgium). 
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Visit Procedures 
At visit 1 (day 1; baseline), patients provided written informed consent o 
participate; conformity with eligibility criteria was assessed; and baseline 
demographic and clinical characteristics (including smoking and drinking hab- 
its; disease history [including osteopenia, osteoporosis, and fractures], and con- 
comitant drug use) were recorded. Patients were randomized to a treatment 
sequence, provided with the appropriate supplement, and asked to return in 
14 days. 
At visit 2 (day 15), patients returned any unused doses, which were counted 
for compliance assessment. Patients completed a 5-variable acceptability ques- 
tionnaire, which used the following widely accepted but not validated 11-point 
rating scales: taking the dose out of the container (scale: 0 = very difficult to 
10 = very easy), taking the dose (scale: 0 = very difficult o 10 = very easy), taste 
(scale: 0 = very bad to 10 = very good), time spent taking the dose (scale: 0 = 
very troublesome to 10 = no problem at all), and general convenience of taking 
the dose (scale: 0 = very difficult o 10 = very easy). All AEs (defined as events 
that occurred after informed consent was provided or worsened if present at 
baseline and identified using patient interview) that occurred between visits 1 
and 2 (period 1) were recorded. Patients received the alternate formulation and 
were again asked to return in 14 days. 
At visit 3 (day 29), unused doses were counted for compliance assessment. 
Patients completed the acceptability questionnaire and a preference question- 
naire, which assessed preference for a formulation (primary end point). AEs 
that occurred between visits 2 and 3 (period 2) were recorded. 
Statistical Analysis 
Sample size was determined based on the primary end point and a previous 
trial with a similar design by Rees and Howe. 8 The null hypothesis was that the 
preference for either trial drug would be 50%, and the alternative hypothesis 
was that the preference for either trial drug would be 60%. According to bino- 
mial theory, inclusion of 200 participants would result in a power of 78% in the 
country-specific statistical analysis. 
P < 0.05 was used to identify statistical significance. Statistical analyses were 
performed for the intent-to-treat (11"l') population, defined as all patients who 
received at least 1 dose of the trial drug. The primary end point was analyzed 
using a logistic regression model equivalent to the Fisher exact test, as de- 
scribed in the article by Gart. 13 Preference for a formulation was the depen- 
dent variable in the logistic regression model; sequence of treatment was the 
independent variable. The intercept in the model provided an estimate of the 
difference between the 2 formulations, and treatment sequence was an estimate 
of the sequence ffect. The secondary efficacy end points (taking the dose out 
of the container, taking the dose, taste, time spent taking the dose, and general 
convenience oftaking the dose) were analyzed using a linear mixed model, with 
treatment and period as fixed effects and number of patients as the random 
26 
J.Y, Reginster et al. 
effect. SAS version 8.2 (SAS Institute Inc., Cary, North Carolina) was used in all 
statistical analyses. 
RESULTS 
Pat ient  Popu la t ion  
The Belgian study comprised 200 patients, 199 of whom received at least 1 
dose of trial d rug and thus were included in the ITT analysis (174 women, 25 men; 
mean age, 66 years [range, 30-87 years]). Although 100 patients were assigned to 
each treatment sequence, some patients were inadvertently given the incorrect 
sequence (number of patients receiving sequence AB, 104; BA, 95). One patient 
did not return for follow-up and so was withdrawn from the analysis. 
One hundred twelve patients (56.3%) were aged >65 years. Sixteen patients 
(8.0%) indicated that they smoked >10 cigars or cigarettes daily, and 27 (13.6%) 
indicated that they drank alcohol daily. There was a history of osteopenia in 
29 patients (14.6%), osteoporosis in 101 (50.8%), and fracture in 53 (26.6%). Comor- 
bid disease was reported in all 199 patients (100.0%), and concomitant drug use 
in 192 (96.5%). One hundred seventy-two patients (86.4%) completed the study. 
Preference 
Preference data were available in 178 patients. Seventy-two f 91 patients 
(79.1%) receiving sequence AB and 57 of 87 (65.5%) receiving sequence BA pre- 
ferred the tablet (both, P < 0.001) (Table I). Overall, 129 patients (72.5%) pre- 
ferred the tablet compared with 34 (19.1%) who preferred the powder and 15 
(8.4%) who had no preference (both, P< 0.001 vs tablet). Except for sex (more 
men [21 of 24 (87.5%)] than women [108 of 154 (70.1%)] preferred the tablet); 
demographic and clinical characteristics (eg, age; smoking and drinking habits; 
history of osteoporosis, osteopenia, and fracture) were not found to be sig- 
nificantly associated with preference (Table II). Seventy-four of 101 patients 
(73.3%) aged >65 years preferred the tablet. 
Table I. Comparison of preferences between 2 oral formulations of a dietary supple- 
ment containing calcium and vitamin D 3 in Belgian adults (no. [%]) at risk for 
calcium and vitamin D deficiencies. 
Treatment Sequence 
Preference 
Chewable Tablet Effervescent Powder None 
AB (n = 91 ) 72 (79.1) 10 (11.0)* 9 (9.9) 
BA (n = 87) 57 (65.5) 24 (27.6)* 6 (6.9) 
Total (N = 178) 129 (72.5) 34 (19.1)* 15 (8.4)* 
A = chewable tablet; B = effervescent powder. 
*P < 0.001 versus chewable tablet. 
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Table II. Preference results, distributed by demographic and clinical characteristics, for 
2 formulations of a dietary supplement containing a combination of calcium 
and vitamin D 3 in Belgian adults (no. [%]) at risk for calcium and vitamin D 
deficiencies.* 
Preference 
All Patients Chewable Tablet Effervescent Powder None 
Variable (N = 178) (n = 129) (n = 34) (n = 15) 
Demographic 
characteristic 
Sex 
Female 154 (86.5) 108 (70.1) 33 (21.4) 13 (8.4) 
Male 24 (13.5) 21 (87.5) 1 (4.2) 2 (8.3) 
Age group, y 
<65 77 (43.3) 55 (71.4) 16 (20.8) 6 (7.8) 
>65 1 01 (56.7) 74 (73.3) 18 (1 7.8) 9 (8.9) 
Clinical 
characteristic 
Smoke >10 U/d t 
Yes 14 (7.9) 11 (78.6) 3 (21.4) 0 (0.0) 
No 164(92.1) 118(72.0) 31 (18.9) 15 (9.1) 
Drink alcohol daily 
Yes 26 (14.6) 22 (84.6) 3 (11.5) 1 (3.8) 
No 1 52 (85.4) 1 07 (70.4) 31 (20.4) 14 (9.2) 
Disease history 
Osteo porosis 
Yes 95 (53.4) 69 (72.6) 17 (1 7.9) 9 (9.5) 
No 83 (46.6) 60 (72.3) 17 (20.5) 6 (7.2) 
Osteopenia 
Yes 26 (14.6) 18 (69.2) 6 (23.1) 2 (7.7) 
No 1 52 (85.4) 111 (73.0) 28 (1 8.4) 13 (8.6) 
Fracture 
Yes 48 (27.0) 34 (70.8) 10 (20.8) 4 (8.3) 
No I 30 (73.0) 95 (73.1) 24 (I 8.5) 11 (8.5) 
*Percentage~ may not total 100 due to rounding. 
tl U = 1 cigar or cigarette. 
Acceptability 
The mean scores o[ all 5 acceptability variables were consistently and sig- 
nificantly higher [or the tablet han for the powder (all, P < 0.001) (Table III). 
The 2 variables for which the scores were most different between the 2 [or- 
mulations were time spent taking the dose (85.2% [or the tablet vs 52.5% [or 
the powder; P < 0.001) and general convenience of taking the dose (83.6% [or 
the tablet vs 51.4% [or the powder; P < 0.001). 
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Table III. Percentages of patients who rated oral formulations as 9 or 10 on the ac- 
ceptability questionnaire. *t 
Scale Chewable Tablet Effervescent Powder 
Taking the dose 
Time spent taking the dose 
Taking the dose out of the container 
General convenience of taking the dose 
Taste 
86.2 59.6 
85.2 52.5 
84.0 56.6 
83.6 51.4 
68.8 56.3 
*The 5-variable acceptability questionnaire used the following widely accepted but not validated 11 - 
point rating scales: taking the do~e out of the container (scale: 0 = very difficult to 10 = very easy), 
taking the dose (scale: 0 = very difficult to 10 = very easy), taste (scale: 0 = very bad to 10 = very 
good), time spent taking the dose (scale: 0 = very troublesome to 10 = no problem at all), and gen- 
eral convenience of taking the dose (scale: 0 = very difficult to 10 = very easy). 
tp < 0.001 between formulas for all 5 variables of acceptability. 
Compl iance  and  To le rab i l i ty  
The compliance analysis included 189 patients. The mean (median) numbers 
of trial doses used were 27.0 (27.0) for the tablet and 24.6 (27.0) for the powder. 
The mean (median) durations of intake were 13.5 (14.0) days for the tablet and 
12.9 (13.0) days for the powder. 
The tolerability analysis of the tablet formulation included 192 patients; 
the powder formulation, 190 patients. Although statistical analysis was not 
performed on the tolerability results, the total number of, most frequent, 
severity of, and causality of AEs were similar between the 2 formulations. 
The most common AEs were gastrointestinal (tablet, 27 patients [14.1%]; 
powder, 31 patients [16.3%]). The most frequently reported AEs were con- 
stipation (tablet, 11 patients [5.7%]; powder, 6 [3.2%]), dyspepsia (tablet, 
4 [2.1%]; powder, 6 [3.2%]), and stomach discomfort (tablet, 4 [2.1%]; pow- 
der, 4 [2.1%]) (Table IV). Of the 79 AEs considered probably or possibly re- 
lated to trial medication, 38 occurred in 29 patients (15.1%) during treat- 
ment with the tablet, and 41 events occurred in 33 patients (17.4%) during 
treatment with the powder. Seven severe AEs were reported: tablet, 6 AEs 
(1 patient [0.5%] each, exacerbated pain, Escherichia pneumonia infection, 
back pain, arthralgia, multiple myeloma, and exacerbated chronic obstruc- 
tive pulmonary disease); powder, 1 AE (back pain [1 patient (0.5%)]). 
Eighteen patients (9.0%) discontinued the trial due to >1 AE (Tables IV and V). 
The most common AEs leading to discontinuation were aggravated constipa- 
tion (tablet, 3 patients (1.6%); powder, 3 [1.6%]), dyspepsia (tablet, 4 [2.1%]; 
powder, 2 [1.1%]), and diarrhea not otherwise specified (tablet, 0 [0.0%]; 
powder, 2 [1.1%]). All participants who discontinued due to an AE recovered 
completely. 
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Table IV. Prevalence of possibly/probably treatment-related adverse events (AEs) with 
2 oral formulations of a dietary supplement containing a combination of 
calcium plus vitamin D 3 in Belgian adults at risk for calcium and vitamin D 
deficiencies,* 
Chewable Tablet 
(n = 192) t 
Effervescent Powder 
(n = 190) ~t 
No. (%) No. of No. (%) No. of 
System/AE of Patients AEs of Patients AEs 
Gastrointestinal 
Constipation 11 (5.7) 11 6 (3.2) 6 
Dyspepsia 4 (2.1) 4 6 (3.2) 6 
Stomach discomfort 4 (2.1) 4 4 (2.1) 4 
Constipation, aggravated 3 (1.6) 3 3 (1.6) 3 
Nausea 2 (1.0) 2 6 (3.2) 6 
Diarrhea NOS 2 (1.0) 2 4 (2.1) 4 
Vomiting NOS 1 (0.5) 1 2 (1.1) 2 
Bleeding hemorrhoids 1 (0.5) 1 0 (0.0) 0 
Dry mouth 1 (0.5) 1 0 (0.0) 0 
Esophagitis, aggravated 1 (0.5) 1 0 (0.0) 0 
Stomatitis 1 (0.5) 1 0 (0.0) 0 
Abdominal distension 0 (0.0) 0 1 (0.5) 1 
Dyspepsia, aggravated 0 (0.0) 0 1 (0.5) 1 
Esophagitis NOS 0 (0.0) 0 1 (0.5) 1 
Flatulence 0 (0.0) 0 1 (0.5) 1 
Gastrointestinal upset 0 (0.0) 0 1 (0.5) 1 
Retching 0 (0.0) 0 1 (0.5) 1 
All 27(14.1) 30 31 (16.3) 37 
General disease/ 
administration site 
Condition aggravated 1 (0.5) 1 1 (0.5) 1 
Pain NOS 1 (0.5) 1 0 (0.0) 0 
All 2 (I.0) 2 I (0.5) I 
Metabolic and nutritional 
Eating disorders I (0.5) I I (0.5) I 
All I (0.5) I I (0.5) I 
Musculoskeletal and 
connective tissue 
Back pain I (0.5) I 0 (0.0) 0 
All 1 (0.5) 1 0 (0.0) 0 
Respiratory, thoracic, 
andmediastinal 
Dry throat 1 (0.5) 1 0 (0.0) 0 
Pharyngitis 0 (0.0) 0 1 (0.5) 1 
All I (0.5) I I (0.5) I 
(continued) 
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Table IV. (Continued) 
Chewable Tablet Effervescent Powder 
(n = 192) t (n = 190)* 
No. (%) No. of No. (%) No. of 
System/AE of Patients AEs of Patients AEs 
Skin and subcutaneous tissues 
Eczema 2 (1.0) 2 0 (0.0) 0 
Rash NOS I (0.5) I 0 (0.(3) 0 
Pruritus 0 (0.0) 0 I (0.5) I 
All 3 (1.6) 2 I (0.5) I 
Total 29 (I 5.I) 38 33 (I 7.4) 41 
NOS = not otherwise specified. 
*Statistical analysis of tolerability was not performed. 
tTwelve patients (6.3%) receiving the chewable tablet discontinued the study due to AEs, including 
dyspepsia (4 patients [2.1%]), and aggravated constipation (2 patients [1.0%]). 
*Six patients receiving the effervescent powder discontinued the study due to AEs, including aggravat- 
ed constipation (3 patients [1.6%]), and diarrhea NOS and dyspepsia (each, 2 patients [1.1 %]). 
Table V. Discontinuations in this study of 2 oral formulations of a dietary supplement 
containing a combination of calcium plus vitamin D 3 in Belgian adults (no. [%]) 
at risk for calcium and vitamin D deficiencies.* 
Population/Reason for Withdrawal 
Treatment Sequence 
AB BA All Patients 
Randomized to treatment 104 (100.0) 96 (100.0) 200 (100.0) 
Informed consent withdrawn; 
no trial medication taken 0 (0) 1 (1.0) 1 (0.5) 
Intent-to-treat population 104 (100.0) 95 (100.0) 199 (100.0) 
Adverse event(s) 
A 8 (Z.Z) 4 (4.2) 12 (6.0) 
B 4 (3.8) 2 (2.1) 6 (3.0) 
Other 
A 1 (1 .(3) 3 (3.2) 4 (2.0) 
B 3 (2.9) 2 (2.1) 5 (2.5) 
A = chewable tablet; B = effervescent powder. 
*No significant between-formulation differences were found. 
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DISCUSSION 
The results of the present study support a general preference for the chewable- 
tablet formulation over the effervescent powder. Acceptability of and prefer- 
ence for pharmacotherapy have been shown to be closely related to compli- 
ance, 2-4,14 which is in turn related to efficacy, especially in the long term. Thus, 
patients may be more compliant with the chewable-tablet formulation of the 
calcium-plus-vitamin D supplement and thus experience better long-term effica- 
cy, reducing the risk for fracture, compared with the powder. 
Several studies have shown that better compliance was reflected in better 
efficacy. Dawson-Hughes tal I showed the importance of long-term compliance 
with calcium and vitamin D supplementation, i  that the beneficial effect on 
BMD (an indicator of fracture risk) in the total body or at any bone site in el- 
derly (age, >65 years) patients did not persist when supplementation was discon- 
tinued. Consistent with this observation, serum osteocalcin concentrations (an 
indicator of bone turnover) returned to near-baseline l vels within 2 years after 
patients discontinued supplementation. 
Furthermore, it has been shown that calcium and vitamin D deficiencies are 
age related. Chapuy et al is found that dietary supplements of calcium and vita- 
min D slowed the rate of bone loss and, in turn, reduced fracture risk. Placebo- 
controlled trials have shown that calcium and vitamin D supplementation given 
for 181G and 36 l~ months significantly reduced the risk for hip and other nonver- 
tebral fractures in elderly patients. 
The success of any treatment strategy in maintaining therapeutic benefit 
depends on compliance, which is closely related to tolerability and acceptability 
of the product. 2-4,14 Marriott ~ and Rees and Howe s found that the acceptability of
taste is related to product preference and willingness to continue treatment on a 
long-term basis. For optimal compliance, the taste, size, and administration for- 
mulation of oral preparations should be acceptable and convenient. Based on 
the results of the previously mentioned studies, acceptability and preference of 
any dietary supplement containing calcium plus vitamin D 3 may influence com- 
pliance in the long term. An expected resulting improvement of BMD will pre- 
vent demineralization, bone loss, and fracture in the long term. However, the 
long-term effects of acceptability of 2 formulations of calcium and vitamin D 
supplements were beyond the scope of this study. Whether similar results can 
be found in long-term treatment periods should be the subject of future studies. 
Based on the differences in formulation and active constituents ofthe 2 supple- 
ments studied, patients' preferences depended on the acceptability and tolerabii- 
ity of the product. The gastrointestinal events experienced by the patients in the 
present study are known to occur during treatment with calcium salts. 
CONCLUSIONS 
In this study of preference for and acceptability of 2 oral formulations (chew- 
able tablet and effervescent powder) of a dietary supplement containing cal- 
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cium plus vitamin D s in Belgian adults at risk for calcium and vitamin D defi- 
ciencies, the chewable tablet was preferred by a significant majority. Based on 
5 variables, the tablet was found to be significantly more acceptable than the 
powder. Tolerability was similar between the 2 formulations. 
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